Skip to main content
SpringerLink
Log in

Dronabinol (Marinol®)

  • Chapter
  • First Online:
Cannabinoids and Pain

Abstract

Dronabinol (Marinol®) is synthetic delta-9-tetrahydrocannabinol (delta-9-THC). It is a Schedule II drug that is FDA approved for anorexia associated with weight loss in patients with AIDS and nausea and vomiting associated with cancer chemotherapy.

Although it is not FDA approved for pain control, there are few reports suggesting its potential role in cancer pain, noncancer pain, neuropathic pain, and central pain.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Marinol (Dronabinol). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf. Accessed 11/7/2020.

  2. Department of Justice. Drug Enforcement Administration. Schedules of controlled substances: placement of FDA-approved products of oral solutions containing dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in schedule II. Fed Regist;82(224) (Wednesday, November 22, 2017). https://www.deadiversion.usdoj.gov/fed_regs/rules/2017/fr1122_6.htm. Accessed on 11/4/2021.

  3. De Vries M, Van Rijckevorsel DC, Wilder-Smith OH, Van Goor H. Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opin Pharmacother. 2014;15:1525–34.

    Article  Google Scholar 

  4. Schimrigk S, Marziniak M, Neubauer C, Kugler EM, Werner G, Abramov-Sommariva D. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur Neurol. 2017;78(5–6):320–9.

    Article  CAS  Google Scholar 

  5. Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017;80(3):441–9.

    Article  CAS  Google Scholar 

  6. Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, et al. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. Ther Drug Monit. 2014;36(2):218–24.

    Article  CAS  Google Scholar 

  7. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–60.

    Article  CAS  Google Scholar 

  8. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477–82.

    Article  Google Scholar 

  9. Carley DW, Prasad B, Reid KJ, Malkani R, Attarian H, Abbott SM, et al. Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. Sleep. 2018;41(1):zsx184. https://doi.org/10.1093/sleep/zsx184.

    Article  Google Scholar 

  10. Bar-Sela G, Zalman D, Semenysty V, Ballan E. The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study. Integr Cancer Ther. 2019;18:1534735419881498.

    Article  CAS  Google Scholar 

  11. Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013;38(10):1984–92.

    Article  CAS  Google Scholar 

  12. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9(3):254–64.

    Article  CAS  Google Scholar 

  13. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329(7460):253.

    Article  CAS  Google Scholar 

  14. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manag. 1995;10(2):89–97.

    Article  CAS  Google Scholar 

  15. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991;40(3):695–700.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Johns Hopkins Hospital, Baltimore, MD, USA

    Juliet Gaisey

  2. Western Reserve Hospital, Center For Pain Medicine, Cuyahoga Falls, OH, USA

    Samer N. Narouze

Authors
  1. Juliet Gaisey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samer N. Narouze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samer N. Narouze .

Editor information

Editors and Affiliations

  1. Western Reserve Hospital, Center For Pain Medicine, Cuyahoga Falls, OH, USA

    Samer N. Narouze

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gaisey, J., Narouze, S.N. (2021). Dronabinol (Marinol®). In: Narouze, S.N. (eds) Cannabinoids and Pain. Springer, Cham. https://doi.org/10.1007/978-3-030-69186-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-69186-8_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-69185-1

  • Online ISBN: 978-3-030-69186-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation